CardioSignal collaborates with Boehringer Ingelheim to improve access for at-home heart monitoring
The collaboration includes making easy-to-use, at-home monitoring of atrial fibrillation available for at-risk individuals in France through a network of 1,000 cardiologists. The initiative aims to reach 5,000 individuals to prevent adverse health outcomes caused by undiagnosed atrial fibrillation.
Atrial fibrillation can be dangerously asymptomatic and is the single most important cause of ischemic stroke. With regular monitoring, atrial fibrillation may be detected early, allowing treatment to start without delay. Early detection is considered to improve outcomes for individuals with atrial fibrillation.
“We are excited to team up with Boehringer Ingelheim for improved heart health. Most premature deaths from heart disease are preventable, which is why lowering the threshold of heart health monitoring is so crucial. At CardioSignal, by focusing on technological development, user experience and scientific research, we drive our mission to improve heart health globally. An important part of this effort is minimizing the burden caused by undetected atrial fibrillation, also among individuals with existing heart conditions like heart failure(1),” says CardioSignal CEO, MD Juuso Blomster.
In this initiative, the CardioSignal application, a CE-certified medical device, is made available by their physician to individuals who are at risk of atrial fibrillation. Known risk factors include for example advanced age, high blood pressure, sleep apnea, diabetes, and other heart conditions such as heart failure. The likelihood of developing atrial fibrillation increases significantly with age. After 40 years of age, every 1 in 4 will develop atrial fibrillation during their lifetime (2).
"CardioSignal represents a major advance, at a time when the number of stroke cases is constantly increasing, with an expected 8% increase in prevalence by 2030. Many cases could be avoided with a more optimal diagnosis of AF. Indeed, AF is responsible for 20 to 30% of ischemic strokes. This new screening tool illustrates Boehringer Ingelheim's commitment to cardiology, particularly in the fight against stroke. This commitment is expressed through several pillars such as innovative therapies, collaboration with healthcare professionals to optimize the care pathway, but also numerous information and prevention actions,” says Edward Hollywood, General Manager Human Health of Boehringer Ingelheim France.
In short:
The initiative will last until summer 2022.
Boehringer Ingelheim provides access to a wide network of cardiologists in France who have the option to offer CardioSignal to their patients.
CardioSignal provides three months’ access to heart monitoring with the CardioSignal application, available for iOS and Android.
Heart monitoring with CardioSignal only requires one minute, twice a day. No other devices other than a smartphone are needed.
Learn more at www.cardiosignal.com.
Further information:
CardioSignal
Juuso Blomster, CEO, juuso.blomster@cardiosignal.com
Juulia Simonen (Communications) juulia.simonen@cardiosignal.com, tel. +358503059018
Boehringer Ingelheim
Sophie Durand, sophie.durand@boehringer-ingelheim.com, tel. +33 (0)1 44 34 68 00
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases. CardioSignal is a mobile application and a certified medical device for the detection of atrial fibrillation. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior. www.cardiosignal.com
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com
Sources:
1. Blomster, J. et al. CardioSignal Smartphone Application Detects Atrial Fibrillation In Heart Failure Population. Presented in AHA 2021 on November 13.
The study examined how the CardioSignal application performs in AFib detection in a specific population of HF patients with a recent HF decompensation event. All patients (N=83) were classified as either having a sinus rhythm or AFib in the ECG analyses.
2. Lloyd-Jones, D. M. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110, 1042–1046, https://doi.org/10.1161/01.CIR.0000140263.20897.42 (2004)
